|
1
|
Matsuda A, Matsuda T, Shibata A, Katanoda
K, Sobue T and Nishimoto HJapan Cancer Surveillance Research Group:
Cancer incidence and incidence rates in Japan in 2008: a study of
25 population-based cancer registries for the Monitoring of Cancer
Incidence in Japan (MCIJ) project. Jpn J Clin Oncol. 44:388–396.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Little AG, Gay EG, Gaspar LE and Stewart
AK: National survey of non-small cell lung cancer in the United
States: epidemiology, pathology and patterns of care. Lung Cancer.
57:253–260. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Finkelstein DM, Ettinger DS and
Ruckdeschel JC: Long-term survivors in metastatic non-small-cell
lung cancer: an Eastern Cooperative Oncology Group Study. J Clin
Oncol. 4:702–709. 1986.PubMed/NCBI
|
|
4
|
Sorensen JB, Hansen HH, Hansen M and
Dombernowsky P: Brain metastases in adenocarcinoma of the lung:
frequency, risk groups, and prognosis. J Clin Oncol. 6:1474–1480.
1988.PubMed/NCBI
|
|
5
|
Hoang T, Xu R, Schiller JH, Bonomi P and
Johnson DH: Clinical model to predict survival in chemonaive
patients with advanced non-small-cell lung cancer treated with
third-generation chemotherapy regimens based on Eastern Cooperative
Oncology Group data. J Clin Oncol. 23:175–183. 2005. View Article : Google Scholar
|
|
6
|
Bauml J, Mick R, Zhang Y, Watt CD, Vachani
A, Aggarwal C, Evans T and Langer C: Determinants of survival in
advanced non-small-cell lung cancer in the era of targeted
therapies. Clin Lung Cancer. 14:581–591. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Travis WD, Brambilla E, Muller-Hermelink
HK and Harris CC: Pathology and genetics of tumours of the lung,
pleura, thymus and heartWorld Health Organization Classification of
Tumours. IARC Press; Lyon: pp. 9–124. 2004
|
|
8
|
Sobin LH, Gospodarowicz MK and Wittekind
C: TNM Classification of Malignant Tumours. 7th. Wiley-Blackwell;
pp. 136–146. 2009
|
|
9
|
Cox DR: Regression models and life tables.
J Roy Statist Soc Ser B Metho. 34:187–220. 1972.
|
|
10
|
Sakurai M, Shinkai T, Eguchi K, et al:
Prognostic factors in non-small cell lung cancer: multiregression
analysis in the National Cancer Center Hospital (Japan). J Cancer
Res Clin Oncol. 113:563–566. 1987. View Article : Google Scholar
|
|
11
|
Borges M, Sculier JP, Paesmans M, et al:
Prognostic factors for response to chemotherapy containing platinum
derivatives in patients with unresectable non-small cell lung
cancer (NSCLC). Lung Cancer. 16:21–33. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Paralkar VR, Li T and Langer CJ:
Population characteristics and prognostic factors in metastatic
non-small-cell lung cancer: a Fox Chase Cancer Center
retrospective. Clin Lung Cancer. 9:116–121. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jacot W, Quantin X, Boher JM, Andre F,
Moreau L, Gainet M, Depierre A, Quoix E, Chevalier TL and Pujol
JLAssociation d'Enseignement et de Recherche des Internes en
Oncologie: Brain metastases at the time of presentation of
non-small cell lung cancer: a multi-centric AERIO analysis of
prognostic factors. Br J Cancer. 84:903–909. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sanchez de Cos J, Sojo Gonzalez MA,
Montero MV, Perez Calvo MC, Vicente MJ and Valle MH: Non-small cell
lung cancer and silent brain metastasis. Survival and prognostic
factors. Lung Cancer. 63:140–145. 2009.PubMed/NCBI
|
|
15
|
Saad F, Lipton A, Cook R, Chen YM, Smith M
and Coleman R: Pathologic fractures correlate with reduced survival
in patients with malignant bone disease. Cancer. 110:1860–1867.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zarogoulidis K, Boutsikou E, Zarogoulidis
P, Eleftheriadou E, Kontakiotis T, Lithoxopoulou H, Tzanakakis G,
Kanakis I and Karamanos NK: The impact of zoledronic acid therapy
in survival of lung cancer patients with bone metastasis. Int J
Cancer. 125:1705–1709. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kagohashi K, Satoh H, Ishikawa H, Ohtsuka
M and Sekizawa K: Liver metastasis at the time of initial diagnosis
of lung cancer. Med Oncol. 20:25–28. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gorg C, Schwerk WB, Wolf M and Havemann K:
Prognostic value of response to chemotherapy using ultrasound in
lung cancer with metastatic liver involvement. Bildgebung.
57:70–73. 1990.PubMed/NCBI
|
|
19
|
Yamamoto N, Tamura T, Fukuoka M and Saijo
N: Survival and prognostic factors in lung cancer patients treated
in phase I trials: Japanese experience. Int J Oncol. 15:737–741.
1999.PubMed/NCBI
|
|
20
|
Nakagawa T, Okumura N, Ohata K, Igai H,
Matsuoka T and Kameyama K: Postrecurrence survival in patients with
stage I non-small cell lung cancer. Eur J Cardiothorac Surg.
34:499–504. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Toloza EM, Harpole L and McCrory DC:
Noninvasive staging of non-small cell lung cancer: a review of the
current evidence. Chest. 123 Suppl 1:137S–146S. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mohammad K and Sadikot RT: Adrenal
insufficiency as a presenting manifestation of nonsmall cell lung
cancer. South Med J. 102:665–667. 2009. View Article : Google Scholar : PubMed/NCBI
|
